First Time Loading...

I-Mab
NASDAQ:IMAB

Watchlist Manager
I-Mab Logo
I-Mab
NASDAQ:IMAB
Watchlist
Price: 1.76 USD -0.28% Market Closed
Updated: May 6, 2024
IMAB
/
Income Statement
/
Revenue

I-Mab
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

I-Mab
Revenue Peer Comparison

Comparables:
6160
1801
603392
300122
300896

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
I-Mab
NASDAQ:IMAB
Revenue
¥27.6m
CAGR 3-Years
-74%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Revenue
¥9.6B
CAGR 3-Years
48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Revenue
¥6.2B
CAGR 3-Years
17%
CAGR 5-Years
266%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Revenue
¥5.5B
CAGR 3-Years
33%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Revenue
¥49.7B
CAGR 3-Years
53%
CAGR 5-Years
65%
CAGR 10-Years
50%
Imeik Technology Development Co Ltd
SZSE:300896
Revenue
¥1.9B
CAGR 3-Years
51%
CAGR 5-Years
54%
CAGR 10-Years
N/A

I-Mab
Revenue Breakdown

Breakdown by Geography
I-Mab

Not Available

Breakdown by Segments
I-Mab

Total Revenue: 27.6m CNY
100%
Licensing And Collaboration: 16.8m CNY
60.8%
Supply Of Investigational Products: 10.8m CNY
39.2%

See Also

What is I-Mab's Revenue?
Revenue
27.6m CNY

Based on the financial report for Dec 31, 2023, I-Mab's Revenue amounts to 27.6m CNY.

What is I-Mab's Revenue growth rate?
Revenue CAGR 5Y
-12%

The average annual Revenue growth rates for I-Mab have been -74% over the past three years , -12% over the past five years .

ALPHA SPREAD
Join more than 134,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.